From Big Pharma’s tricky PR maneuvering on drug prices to potential purges of non-loyalists at the VA to (my personal favorite) the benefits of a four-day workweek, we have been overrun with health news this week.
Here’s what you need to know and might have missed:
Pharma’s once again grabbing headlines this week, as Novartis and Merck follow in Pfizer’s footsteps in lowering drug prices. But just as with Pfizer, there’s some fine print the companies probably don’t want you to read.
Novartis, for one, is in the middle of a scandal over its contract with President Donald Trump’s personal attorney (and more news just came out over the depth of that connection). So the good PR comes at quite a convenient time. And Merck’s choices of what prices to lower seem very strategic. (For example: It cut the cost of its hep C drug鈥 which had never gained traction in the U.S. anyway. The move could actually boost sales for the company.)
A whistleblower (with the FBI code name “Pampers”!) exposes drug companies’ brazen and illegal maneuvering to get on Medicaid’s preferred drug list in this captivating must-read investigation from NPR and the Center for Public Integrity.
Uh, thanks but no thanks? The聽National Federation of Independent Business, after decades (decades!) of lobbying for association health plans, is now calling Trump’s offering unworkable. Not worth the effort to even set them up, it says.
There’s also been some movement that may reveal the administration’s plan to resume those payments to insurers it froze so abruptly recently.
A tidal wave of reassignments and retirements of Veterans Affairs employees perceived as disloyal to Trump is raising eyebrows this week right ahead of nominee Robert Wilkie’s likely confirmation ().
This is going to be a story that keeps cropping up over the next few months, but it’s still worth noting: There’s a health care wedge driving deeper and deeper into the Democratic Party, and it doesn’t seem likely to be resolved anytime soon. Progressives are gung-ho about “Medicare for All,” while moderates insist on sticking with shoring up the health law.
Either choice is a gamble: The GOP is ready to go with counter-rhetoric for the former (like, “It will break Medicare”), while a big part of the Democratic base is tired of baby steps over the health law.
Getting funding for medical research is already a dog-eat-dog process, but with the immigration crisis burning through the Department of Health and Human Services’ money, advocates are worried about what public health programs are losing out because of it.
And if all that wasn’t enough news for you, here’s my miscellaneous file for the week: CRISPR gene-editing technology has had people salivating over miracle cures, but new studies are finding that it’s wreaking absolute havoc on patients’ DNA; experts are seeing disturbing parallels between today鈥檚 use of anti-anxiety meds and the early days of the opioid epidemic; if a couple who froze fertilized embryos splits up, who gets to make the decision if one of them wants to have the baby?; and there’s been a recent spate of classic psychological experiments that have been overturned. What does that say for the future of the study of the mind?
Now what you’ve all been waiting for: 聽has proven so successful, the firm that ran it wants to make the change permanent. Go ahead, send this story around!
